Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All N‑acetylcysteine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchN-acetylcysteineN-acetylcys.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -135% unadjusted Improvement Relative Risk N-acetylcysteine  Ramadhan et al.  LATE TREATMENT Is late treatment with N-acetylcysteine beneficial for COVID-19? Prospective study of 91 patients in Indonesia (Jun 2020 - Jul 2021) Study underpowered to detect differences c19early.org Ramadhan et al., Indonesian J. Tropica.., Dec 2021 Favors N-acetylcysteine Favors control

The Effects of N-Acetylcysteine as Adjuvant Therapy To Reduce TNF-Α Level And Increase SPO2/FIO2 Ratio In Improving Hypoxemia In COVID-19 Patients

Ramadhan et al., Indonesian Journal of Tropical and Infectious Disease, 9:3
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
14th treatment shown to reduce risk in February 2021
 
*, now known with p = 0.000034 from 24 studies, recognized in 3 countries.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Prospective study with 75 NAC patients and 16 control patients, showing no significant difference in mortality.
This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
risk of death, 134.7% higher, RR 2.35, p = 0.68, treatment 11 of 75 (14.7%), control 1 of 16 (6.2%), unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ramadhan et al., 27 Dec 2021, prospective, Indonesia, peer-reviewed, 6 authors, study period June 2020 - July 2021.
This PaperN-acetylcys..All
The Effects of N-Acetylcysteine as Adjuvant Therapy To Reduce TNF-Α Level And Increase SPO2/FIO2 Ratio In Improving Hypoxemia In COVID-19 Patients
Fitratul Ramadhan, Ngakan Putu, Parsama Putra, Ungky Agus Setyawan, Susanthy Djajalaksana, Aditya Sri, Harun Al Rasyid
Tumor Necrosis Factor Alpha (TNF-α) is a pro-inflammatory cytokine that plays a crucial role in COVID-19 disease
ACKNOWLEDGEMENT This research received grant from COVID Research and Innovation Consortium by LPDP-RistekBrin. CONFLIC OF INTEREST The authors declare that they have no conflict of interest. REFERENCE 1. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. this study prove that there is the involvement of TNF-α in the mechanism of action of NAC. NAC interferes with the NLRP3 inflammasome pathway by suppressing the expression of NLRP3 and caspase-1 activation mRNA. NAC decreased IL1β, IL18, IL6 and TNF-ɑ in vitro. NAC inhibits downstream activity post-TNF-α receptor activation, and under oxidative stress, NAC inhibits World Health CONCLUSION This finding is by the previous studies, in which Changes in TNF-α levels and alterations in SpO2/FiO2 ratio of COVID-19 patients in the group without adjuvant NAC therapy showed a positive correlation. On the other hand, in the group that did not receive adjuvant NAC therapy, the correlation coe cient was negative and not significant. it was found that the administration of NAC can increase the SpO2/FiO2 ratio. The conclusions of TNF-α and IL-6 gene expression. 9. De Flora S, Balansky R, La Maestra S. Rationale for using changes in TNF-ɑlevels and diferences in the SpO2/FiO2 ratio in COVID-19 patients who did not receive adjuvant NAC therapy. There was a significant decrease in TNF-ɑ levels a fter NA C a dministration a s a djuvants. I n addition, there was also a substantial increase in the SpO2FiO2 ratio after administration of adjuvant..
References
Alamdari, Moghaddam, Amini, Keramati, Zarmehri et al., Application of methylene blue-vitamin C-N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial, European journal of pharmacology
Avdeev, Gaynitdinova, Merzhoeva, Berikkhanov, N-acetylcysteine for the treatment of COVID-19 among hospitalized patients, The Journal of Infection
De Alencar, Moreira, Müller, Chaves, Fukuhara et al., A double-blind, randomized, placebo-controlled trial with N-acetylcysteine to treat severe acute respiratory syndrome caused by Coronavirus Disease 2019 (COVID-19), Clinical Infectious Diseases
Dinicola, De Grazia, Carlomagno, Pintucci, Wu et al., N-acetylcysteine as a potent molecule to destroy bacterial biofilms. A systematic review, International Journal of Infectious Diseases
Furman, Campisi, Verdin, Carrera-Bastos, Targ et al., Chronic inflammation in the etiology of disease across the life span, Nature medicine
Gallo Marin, Aghagoli, Lavine, Yang, Si et al., Predictors of COVID-19 severity: A literature review, Reviews in medical virology
Griendling, Sorescu, Ushio-Fukai, NAD (P) H oxidase: role in cardiovascular biology and disease, Circulation research
Hasan, N-acetylcysteine in Severe COVID-19: The Possible Mechanism, Int J Infect
Ibrahim, Smith, Lewis, Kon, Goldenberg et al., Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine, Clinical Immunology
Ijtid, None
Li G Fan, Coronavirus infections and immune responses, Journal of Medical Virology
Niles, Gogesch, Kronhart, Iannazzo, Kochs et al., Macrophages and Dendritic Cells Are Not the Major Source of Pro-Inflammatory Cytokines Upon SARS-CoV-2 Infection, Frontiers in Immunology
Poe, Corn, N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2, Medical hypotheses
Shah, Formal, Alam, Ganguly, Chattopadhyay, Overview of the immune response during SARS-CoV-2 infection: lessons from the past, Frontiers in immunology
Shi, Yang, Zhou, Xi, Sun et al., Activated carbon N-acetylcysteine microcapsule protects against nonalcoholic fatty liver disease in young rats via activating telomerase and inhibiting apoptosis, PLoS One
Silva, Therapeutic approaches for tumor necrosis factor inhibition, Brazilian Journal of Pharmaceutical Sciences
Wong, Lee, Kua, N-Acetylcysteine as Adjuvant Therapy for COVID-19-A Perspective on the Current State of the Evidence, Journal of inflammation research
Zhang, Ju, Ma, Wang, N-acetylcysteine improves oxidative stress, and inflammatory response in patients with community-acquired pneumonia: A randomized controlled trial, Medicine
Šalamon, Kramar, Pirc Marolt, Poljšak, Milisav, Medical and Dietary Uses of N-Acetylcysteine, Antioxidants
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit